Twist Bioscience Announces Fireside Chat and Presentation at BIO Digital
June 14 2021 - 7:00AM
Business Wire
-- CEO Emily Leproust to Discuss DNA
Synthesis Industry and Broad Applications of Synthetic DNA in
Diagnostics, Therapeutics and More --
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that CEO Emily
Leproust will participate in a fireside chat at the BIO Digital
conference being held virtually from June 10-11 and 14-18, 2021.
Dr. Leproust’s chat with moderator Catherine Schulte, Senior
Research Analyst from Baird will be shown at 3 pm EDT on June 17
and will cover the synthetic biology revolution, how making
synthetic DNA at scale enables applications in diagnostic tools,
therapeutic antibody discovery and development, and more.
Aaron Sato, Ph.D., Twist’s chief scientific officer, will also
provide an overview of Twist Biopharma’s differentiated antibody
discovery and optimization platform, which will be available on
demand to registered attendees during the conference. The
presentation can be accessed from the BIO Digital website at
https://www.bio.org/events/bio-digital/sessions/806568.
An overview of Twist Bioscience is available on demand here.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation Twist’s ability to make the
Twist Diversity SNP panel broadly available to customers in Spring
2021, the Twist Diversity SNP panel’s ability to help data centers
consolidate their data generation costs and physical footprints,
ability to be iterated quickly and role in future of disease marker
testing, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of a significant customer; risks of third party
claims alleging infringement of patents and proprietary rights or
seeking to invalidate Twist Bioscience’s patents or proprietary
rights; and the risk that Twist Bioscience’s proprietary rights may
be insufficient to protect its technologies. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s
business in general, see Twist Bioscience’s risk factors set forth
in Twist Bioscience’s Quarterly Report Form 10-Q filed with the
Securities and Exchange Commission on February 9, 2021 and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Twist Bioscience specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005178/en/
Angela Bitting SVP, Corporate Affairs 925-202-6211
abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024